The following abstracts represent the oral presentations given at IWWM-12 (Prague-2024), Session 22: Clinical Trials in Progress for WM I
Session Chairs: Jeffrey Matous, Shayna Sarosiek
Carfilzomib With and Without Ibrutinib in Frontline and Relapsed/Refractory WM (CZAR-1) Dimopoulos (Greece)
Rainbow Trial: Ibrutinib Rituximab vs. DRC in Newly diagnosed WM Auer (UK)
Zanubrutinib plus Benda-R in Newly diagnosed WM Yi (China)
Pirtobrutinib and Venetoclax in relapsed or refractory WM Castillo (USA)